Condition
Life Threatening Diseases
Estimated Enrollment: 185
Age Group: 15 Years to 70 Years (Child, Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: CSTI571B2225
Study First Received: September 9, 2005
Last Updated: November 16, 2016
Estimated Primary Completion Date: January 2007
Primary Outcome Measures:
To examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate-sensitive tyrosine kinases|To identify the contribution of specific protein tyrosine kinases (PTKs) of that specific disease|To assess the safety and tolerability of Imatinib mesylate|To evaluate the pharmacokinetic profile of Imatinib mesylate|To assess, where feasible, the functional significance of relevant signal-transduction components in target tissues
Sponsors and Collaborators:
Novartis Pharmaceuticals|Novartis
Website Link: https://ClinicalTrials.gov/show/NCT00154388
